Skip to main content
HR 3392 113th Congress House Health Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Fraud offenses and financial crimes Government studies and investigations Health care costs and insurance Health information and medical records Insurance industry and regulation Internet and video services Internet, web applications, social media Medicare Prescription drugs Retail and wholesale trades

Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013

Introduced: October 30, 2013 Introduced by: Bilirakis, Gus M. Republican · Florida See on congress.gov
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 1, 2013
Referred to the Subcommittee on Health.
Oct 30, 2013
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 30, 2013
Introduced in House
 Plain-English summary Congressional Research Service

Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act (SSA) to establish a safe pharmacy access program under which a prescription drug plan (PDP) sponsor (or a Medicare Advantage (MA) organization offering an MA-PD plan) shall have in place procedures designed to prevent fraud and abuse in the dispensing of certain controlled substances under Medicare part D.

Allows a PDP sponsor to suspend payments and clean claim notifications to a pharmacy pending an investigation of a credible allegation of fraud against the pharmacy, unless the Secretary determines there is a good cause not to suspend payments.

Directs the Secretary of Health and Human Services (HHS), under contracts entered into under the Medicare integrity program with Medicare drug integrity contractors (MEDICs), to authorize such MEDICs to obtain prescription and medical records directly from entities such as pharmacies, PDPs, and physicians. Requires a MEDIC to acknowledge receipt of a PDP sponsor referral of information for investigation, report back to the sponsor the investigation results within 45 days, and share them with appropriate agencies.

Requires electronic transmission (e-prescribing) of prescriptions for certain covered Medicare part D controlled substances.

What's happening now November 1, 2013

Referred to the Subcommittee on Health.

 Committees of jurisdiction 3